Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery

Gomez, Alexan I.; Acosta, Maria F.; Muralidharan, Priya; Yuan, Jason X.‐J.; Black, Stephen M.; Hayes, Don; Mansour, Heidi M.

doi:10.1016/j.pupt.2020.101975

Cited by 29 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intramuscularly administered COVID-19 vaccines that are being administered currently present a significant limitation, which is the lack of mucosal immunization: given that the primary route for transmission of SARS-CoV-2 is the respiratory mucosa in the respiratory tract via inhalation of small respiratory droplets from infected individuals [ 127 ]. To date, the COVID-19 vaccine that has advanced to phase three in clinical trials has no expectations to provide mucosal immunity in nasal cavities nor lung tissue, although they demonstrate T cell activation and the stimulation of serum neutralizing antibodies.…”

Section: Inhaled Covid-19 Vaccines and Their Current Clinical Statusmentioning

confidence: 99%

Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection

et al. 2021

Self Cite

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID-19) is caused by coronavirus-2 (SARS-CoV-2) and has produced a global pandemic. As of 22 June 2021, 178 million people have been affected worldwide, and 3.87 million people have died from COVID-19. According to the Centers for Disease Control and Prevention (CDC) of the United States, COVID-19 virus is primarily transmitted between people through respiratory droplets and contact routes. Since the location of initial infection and disease progression is primarily through the lungs, the inhalation delivery of drugs directly to the lungs may be the most appropriate route of administration for treating COVID-19. This review article aims to present possible inhalation therapeutics and vaccines for the treatment of COVID-19 symptoms. This review covers the comparison between SARS-CoV-2 and other coronaviruses such as SARS-CoV/MERS, inhalation therapeutics for the treatment of COVID-19 symptoms, and vaccines for preventing infection, as well as the current clinical status of inhaled therapeutics and vaccines.

show abstract

Section: Inhaled Covid-19 Vaccines and Their Current Clinical Statusmentioning

confidence: 99%

Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, vaccine administration routes have advantages and disadvantages in relation to virus transmission. Certainly, it should be noted that intramuscular COVID-19 vaccines, which are currently administered, have an important limitation: the lack of mucosal immunization, since the primary route for SARS-CoV-2 transmission is the respiratory mucosa in the respiratory tract [124].…”

Section: The Immunity and Virus Transmission After Vaccinationmentioning

confidence: 99%

What Happens to the Immune System after Vaccination or Recovery from COVID-19?

Tiyo

Schmitz

Ortega

et al. 2021

Life

View full text Add to dashboard Cite

Due to its leading role in fighting infections, the human immune system has been the focus of many studies in the context of Coronavirus disease 2019 (COVID-19). In a worldwide effort, the scientific community has transitioned from reporting about the effects of the novel coronavirus on the human body in the early days of the pandemic to exploring the body’s many immunopathological and immunoprotecting properties that have improved disease treatment and enabled the development of vaccines. The aim of this review is to explain what happens to the immune system after recovery from COVID-19 and/or vaccination against SARS-CoV-2, the virus that causes the disease. We detail the way in which the immune system responds to a SARS-CoV-2 infection, including innate and adaptive measures. Then, we describe the role of vaccination, the main types of COVID-19 vaccines and how they protect us. Further, we explain the reason why immunity after COVID-19 infection plus a vaccination appears to induce a stronger response compared with virus exposure alone. Additionally, this review reports some correlates of protection from SARS-CoV-2 infection. In conclusion, we reinforce that vaccination is safe and important in achieving herd immunity.

show abstract

“…However, most of the clinical studies were performed using liquid AmB formulations designed for parenteral administration that have been repurposed for nebulization and used off-label to treat lower airway infections; additionally, the optimal drug dosing often remains undefined. New formulations of AmB have been recently developed for administration by DPI but in vivo studies have not been performed on these formulations [ 25 , 26 ].…”

Section: Resultsmentioning

confidence: 99%

“…Median plasma concentrations were 100 times lower twelve hours after the last nebulization in the inhalation group, who received 40 mg b.i.d for two days, compared to the oral group (400 mg b.i.d at day 1, 200 mg b.i.d at day 2) (8 vs. 1224 ng/mL, p < 0.0001) [ 137 ]. There was a non-significant trend towards a higher median ELF/plasma concentration ratio in the inhalation group (21, 95% CI [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ,…”

Section: Resultsmentioning

confidence: 99%

Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections

et al. 2022

View full text Add to dashboard Cite

Pulmonary mold infections are life-threatening diseases with high morbi-mortalities. Treatment is based on systemic antifungal agents belonging to the families of polyenes (amphotericin B) and triazoles. Despite this treatment, mortality remains high and the doses of systemic antifungals cannot be increased as they often lead to toxicity. The pulmonary aerosolization of antifungal agents can theoretically increase their concentration at the infectious site, which could improve their efficacy while limiting their systemic exposure and toxicity. However, clinical experience is poor and thus inhaled agent utilization remains unclear in term of indications, drugs, and devices. This comprehensive literature review aims to describe the pharmacokinetic behavior and the efficacy of inhaled antifungal drugs as prophylaxes and curative treatments both in animal models and humans.

show abstract

Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery

Cited by 29 publications

References 31 publications

Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection

Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection

What Happens to the Immune System after Vaccination or Recovery from COVID-19?

Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections

Contact Info

Product

Resources

About